• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

作者信息

Merz Maximilian, Hielscher Thomas, Mai Elias Karl, Seckinger Anja, Hose Dirk, Jauch Anna, Sauer Sandra, Luntz Steffen, Bertsch Uta, Raab Marc S, Neben Kai, Salwender Hans, Blau Igor W, Lindemann Hans-Walter, Dürig Jan, Scheid Christof, Haenel Mathias, Weisel Katja, Weber Tim, Delorme Stefan, Goldschmidt Hartmut, Hillengass Jens

机构信息

Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

出版信息

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3.

DOI:10.1038/s41408-019-0235-3
PMID:31455768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6712022/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fd1/6712022/ef69ac0b7408/41408_2019_235_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fd1/6712022/7a1ce04998fe/41408_2019_235_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fd1/6712022/ef69ac0b7408/41408_2019_235_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fd1/6712022/7a1ce04998fe/41408_2019_235_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fd1/6712022/ef69ac0b7408/41408_2019_235_Fig2_HTML.jpg

相似文献

1
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.治疗后局灶性病变的囊性转化与缓解相关，但在骨髓瘤中是不良预后。
Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3.
2
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、双模拟、随机、对照、3 期研究。
Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.
3
MRI negative meningeal myeloma with abducens nerve palsies responding to intrathecal chemotherapy.MRI检查呈阴性的脑膜骨髓瘤伴展神经麻痹，鞘内化疗有效
J Neurol Sci. 2014 Dec 15;347(1-2):359-60. doi: 10.1016/j.jns.2014.10.005. Epub 2014 Oct 29.
4
Remission of collapsing focal segmental glomerulosclerosis following chemotherapy for myeloma.骨髓瘤化疗后塌陷型局灶节段性肾小球硬化症缓解
Am J Kidney Dis. 2004 Feb;43(2):e10-2. doi: 10.1053/j.ajkd.2003.10.036.
5
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.新诊断多发性骨髓瘤患者接受卡非佐米、来那度胺和地塞米松治疗的缓解率和无进展生存期：一项 2 期临床试验的 5 年随访结果。
JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457.
6
Severe amyloidosis with mild multiple myeloma--an unusual course.伴有轻度多发性骨髓瘤的严重淀粉样变性——一个不寻常的病程。
Haematologia (Budap). 2000;30(1):55-9. doi: 10.1163/15685590051129904.
7
Proliferative glomerulonephropathy in multiple myeloma.多发性骨髓瘤中的增殖性肾小球肾炎
J Pathol. 1980 Apr;130(4):229-36. doi: 10.1002/path.1711300404.
8
Extensive skeletal involvement detected by gallium-67 citrate in a patient with multiple myeloma.
Clin Nucl Med. 1988 Mar;13(3):179-81. doi: 10.1097/00003072-198803000-00009.
9
A case of multiple myeloma with navicular bone involvement.1例累及舟状骨的多发性骨髓瘤。
Scott Med J. 2017 Nov;62(4):152-155. doi: 10.1177/0036933017727962. Epub 2017 Sep 29.
10
Hyperammonemic encephalopathy in multiple myeloma.多发性骨髓瘤中的高氨血症性脑病
Haematologica. 1998 Oct;83(10):956-7.

引用本文的文献

1
[Potential of radiomics and artificial intelligence in myeloma imaging : Development of automatic, comprehensive, objective skeletal analyses from whole-body imaging data].[放射组学和人工智能在骨髓瘤成像中的潜力：从全身成像数据开发自动、全面、客观的骨骼分析]
Radiologe. 2022 Jan;62(1):44-50. doi: 10.1007/s00117-021-00940-1. Epub 2021 Dec 10.
2
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.多发性骨髓瘤治疗反应和微小残留病的影像学：WB-MRI 和 PET/CT 的现状。
Skeletal Radiol. 2022 Jan;51(1):59-80. doi: 10.1007/s00256-021-03841-5. Epub 2021 Aug 7.
3

本文引用的文献

1
Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.IFM/DFCI 2009试验中纳入的有症状多发性骨髓瘤患者在诊断时及维持治疗前进行磁共振成像和[F]氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描的前瞻性评估：IMAJEM研究结果
J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975. Epub 2017 Jul 7.
2
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
3
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
骨髓瘤微小残留病灶：应用于临床护理和新药注册。
Clin Cancer Res. 2021 Oct 1;27(19):5195-5212. doi: 10.1158/1078-0432.CCR-21-1059.
4
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients.成像在多发性骨髓瘤患者微小残留病评估中的作用
J Clin Med. 2020 Oct 31;9(11):3519. doi: 10.3390/jcm9113519.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.皮下注射与静脉注射硼替佐米用于新诊断多发性骨髓瘤的两种不同诱导治疗：前瞻性GMMG-MM5试验的中期分析
Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.
4
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.一种基于磁共振成像的预后评分系统，用于预测适合移植的多发性骨髓瘤患者的预后。
Haematologica. 2015 Jun;100(6):818-25. doi: 10.3324/haematol.2015.124115. Epub 2015 Mar 20.
5
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.硼替佐米、环磷酰胺和地塞米松（VCD）与硼替佐米、多柔比星和地塞米松（PAd）在新诊断骨髓瘤中的 III 期临床试验。
Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.
6
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.国际骨髓瘤工作组更新了多发性骨髓瘤的诊断标准。
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
7
Therapy monitoring of skeletal metastases with whole-body diffusion MRI.利用全身扩散磁共振成像对骨转移进行治疗监测。
J Magn Reson Imaging. 2014 May;39(5):1049-78. doi: 10.1002/jmri.24548. Epub 2014 Feb 10.
8
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.髓外疾病预示着多发性骨髓瘤的预后不良，即使在新型药物时代，高风险疾病中也存在过度表达。
Haematologica. 2012 Nov;97(11):1761-7. doi: 10.3324/haematol.2012.065698. Epub 2012 Jun 11.
9
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.自体干细胞移植前后磁共振成像的变化与多发性骨髓瘤的反应和生存相关。
Haematologica. 2012 Nov;97(11):1757-60. doi: 10.3324/haematol.2012.065359. Epub 2012 Jun 11.
10
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.弥散性骨髓受累的磁共振成像与新诊断、有症状的多发性骨髓瘤患者的高危细胞遗传学和不良预后相关：228 例患者的单中心经验。
Am J Hematol. 2012 Sep;87(9):861-4. doi: 10.1002/ajh.23258. Epub 2012 May 28.